Ketty Peris

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow‐up study focusing on the late toxicities

Summary Background and Objectives Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC). Patients and Methods We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with...